newsfilter
← Latest News
Business Wire·

Agenus Announces Updated NEST Phase 2 Publication Reporting Deep Pathologic Responses and No Observed Recurrences with Neoadjuvant BOT+BAL in Resectable Colon Cancer

No colorectal cancer recurrences observed at updated median follow-up of 32.2 months in NEST-1 and 23.5 months in NEST-2 In pMMR/MSS tumors, neoadjuvant BOT+BAL achieved 59% pathologic response, including 41% major